ClinicalTrials.gg
Active, not recruitingNCT05853354Updated Apr 26, 2024

Comparative Efficacy, Safety, PK, and Immunogenicity Study

A Phase 3 interventional study of Denosumab in Osteoporosis, Postmenopausal, sponsored by Luye Pharma Group Ltd.. Active, not recruiting at 39 sites in 5 countries. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-04-26.

Sponsored by Luye Pharma Group Ltd. · Phase 3, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Planned enrollment
13th of 31
392 · median 278
Started
2023
the only one that year
Phase 3
17 of 31
1 open now
Registered
31st of 31
by date
Lead sponsor
1 of 31
Luye Pharma Group Ltd.

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 13th largest by planned enrollment, is the only one that started in 2023, is one of 17 in phase 3, and was the 31st registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 60 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.

Read the detailed description

This is a randomized, double-blind, parallel-group, active-controlled, comparative study (Main Period) with a Transition Period to compare the efficacy, PD, safety, PK, and immunogenicity of LY06006 and EU-Prolia among female participants with postmenopausal osteoporosis.

Participants will go through a Screening Period within 35 days prior to first dosing. After signing the informed consent form (ICF), participants will be screened for age, menopausal status, and vitamin D levels, in addition to other inclusion/exclusion criteria. Participants will also undergo a screening DXA examination. Eligibility is based on the absolute value consistent with a T-score ≤ -2.5 and ≥ -4.0 at the lumbar spine.

Main Period Upon completing all screening assessments and meeting all eligibility criteria, participants will enter the Main Period of the study. The Main Period will last 12 months where participants will be randomized in a 1:1 ratio to receive either a dose (60 mg/1 mL) of LY06006 or EU-Prolia subcutaneously at the Baseline Visit (Day 1) and Month 6. All participants will receive daily supplements of elemental calcium (at least 1000 mg) and vitamin D (at least 400 IU). Study visits will occur at the Baseline Visit (Day 1), and at Months 0.5, 1, 2, 3, 6, 9, and 12.

Follow-up BMD assessment will be done at Months 6 and 12. Blood sampling for PD, safety, PK, and immunogenicity will be done at the Baseline Visit (Day 1), and at Months 0.5, 1, 2, 3, 6, 9, and 12.

Transition Period The Transition Period will be conducted in all participants who completed the Main Period of the study. At Month 12, participants who received EU-Prolia in the Main Period will be re-randomized in a 1:1 ratio to either be transitioned to receive a dose of LY06006 or continue on EU-Prolia subcutaneously. Participants who received LY06006 in the Main Period will be re-randomized to continue to receive LY06006 in the Transition Period. All participant assignment during the Transition Period will be performed via the interactive response technology (IRT) system to maintain the blind of treatment assignment.

Blood sampling for PD, safety, PK, and immunogenicity will be done at Months 15 (PK and immunogenicity only) and 18. End of study (EoS) assessments will be performed at Month 18 or at the time of early discontinuation or withdrawal of the participant. The duration of the clinical phase for participants from the Screening Period until the EoS Visit is approximately 19 months (up to 5 weeks of Screening Period, 12 months of Main Period, and 6 months of Transition Period).

03

Conditions studied

  • Osteoporosis, Postmenopausal

Keywords

  • Comparative efficacy;safety;PK; immunogenicity; biosimilar
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

  1. Participant is ≥ 60 to ≤ 90 years of age inclusive, at the time of signing the .

    Type of Participant and Disease Characteristics

  2. Participant is an ambulatory woman (defined as lack of menstrual period for at least 12 months prior to Screening Visit, for which there is no other obvious pathological or physiological cause).

    • Serum FSH test can be done at the Screening Visit in case of uncertainty.
    • Female participants who underwent bilateral oophorectomy (with or without hysterectomy) at least 6 weeks prior to the Screening Period are eligible to participate.
  3. Participant is diagnosed with osteoporosis, with absolute BMD consistent with a T-score of ≤ -2.5 and ≥ -4.0 at the lumbar spine (L1-L4 region) as measured by DXA at the Screening Visit.
  4. Participant has at least two lumbar vertebrae in L1-L4 region and one hip evaluable by DXA for BMD measurement at the Screening Visit.

Weight 5. Participant has body weight ≥ 50 kg and ≤ 90 kg at Screening. Informed Consent 6. Participant is able to read and understand, and willing to provide signed informed consent as described in Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

-

Exclusion Criteria:

Medical Conditions

  1. Participant has a history and/or presence of any severe or more than two moderate vertebral fractures as determined by central reading of lateral spine X-ray at Screening Visit.
  2. Participant has a history and/or presence of hip fracture.
  3. Participant has a history and/or presence of atypical femur fracture.
  4. Participant presents with any active healing fracture, per assessment of the Investigator.
  5. Participant has a history of bilateral hip replacement (unilateral is allowed if the other hip is evaluable by DXA).
  6. Participant has history and/or presence of osteonecrosis of the external auditory canal.
  7. Evidence of any of the following conditions which may affect BMD or interfere with the interpretation of the findings:

    1. Participant has a history of bone disease e.g., osteomalacia, osteopetrosis, Paget's disease, or osteogenesis imperfecta.
    2. Participant has a history of metabolic or other endocrinologic diseases such as Cushing's disease, hyperprolactinemia, hypopituitarism, acromegaly, malabsorption syndrome (or any gastrointestinal disorders associated with malabsorption, e.g., Crohn's disease and chronic pancreatitis).
    3. Participant has a history of chronic inflammatory diseases, obvious sclerosis, osteophytosis, severe scoliosis, or other degenerative changes due to other co-morbidities.
    4. Participant has a history or current hyperparathyroidism or hypoparathyroidism. Note: Mild non- secondary hyperparathyroidism may be acceptable upon discussion with the Medical Monitor.
    5. Participant has current uncontrolled hyperthyroidism or hypothyroidism. Note: Participants with hypothyroidism who are on stable thyroid hormone replacement therapy may be allowed per the following criteria:

      • If TSH level is within normal range, the participant is eligible.
      • If TSH level is elevated (> 5.5 μIU/mL and ≤ 10.0 μIU/mL) and serum free T4 is within normal range, the participant is eligible. If TSH is below the lower level of normal, the participant should be excluded.
    6. Participant has other disease conditions where there is bone/joint involvement (e.g., rheumatoid arthritis, ankylosing spondylitis, gout, multiple myeloma, achondroplasia, bone , renal osteodystrophy, osteomyelitis).
  8. Participant has hypocalcemia (defined as albumin adjusted serum calcium level \< 2.0 mmol/L [8.0 mg/dL] Grade 2 per version 5.0) or hypercalcemia (defined as albumin adjusted serum calcium levels > 2.62 mmol/L [10.50 mg/dL]).
  9. Participant has vitamin D deficiency (defined as 25-hydroxy vitamin D level \< 20 ng/mL [\< 50 nmol/L]).

    Note: Oral replenishment of vitamin D is permitted at the discretion of the Investigator and in accordance with local standard of care during the Screening Period. Participants can be enrolled if a repeat test (post supplementation) prior to enrollment shows corrected 25-hydroxy vitamin D level ≥ 20 ng/mL (≥ 50 nmol/L).

  10. Participant has any (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years.
  11. Participant has known history of liver cirrhosis.
  12. Participant has known history of , , or infection, or an active infection including, but not limited to SARS-CoV-2, tests positive for hepatitis B (positive HBsAg, positive anti-HBc with negative anti-HBs), hepatitis C (hepatitis C antibody), or HIV antibody during the Screening Period.
  13. Participant has oral or dental conditions:

    1. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.
    2. Active dental or jaw condition which requires oral surgery.
    3. Invasive dental procedure planned during the study or within the past 6 months (e.g., tooth extraction, dental implants, oral surgery).
    4. Non-healed dental or oral surgery.
    5. Active periodontal disease.
    6. Poor oral hygiene.
  14. Participant has a history of major surgery within 8 weeks prior to the Screening Period or planned, anticipated major surgery during the study.
  15. Participant has a history and/or presence of significant cardiac disease or abnormalities indicating significant risk for participating in the study as judged by the Investigator.

    Prior/Concomitant Therapy

  16. Participant shows to denosumab therapy (e.g., hypocalcemia), or calcium or vitamin D supplementation before starting study intervention administration.
  17. Participant requires ongoing use of any osteoporosis treatment (other than calcium and vitamin D supplements).
  18. Use of any of the below medications that can affect BMD:

    l. Denosumab used at any time prior to Screening Visit.

    1. Oral bisphosphonates at any dose for osteoporosis treatment:

      • Used for > 3 years cumulatively at Screening Visit.
      • At any dose used within 1 year prior to Screening Visit (if ≤ 3 years of use cumulatively).
    2. Intravenous bisphosphonate at any dose within 5 years prior to Screening Visit.
    3. PTH or PTH analogues at any dose within 2 years prior to Screening Visit.
    4. Systemic HRT (oral or transdermal estrogen), SERMs, tibolone, aromatase inhibitors, or androgens at any dose within 1 year prior to Screening Visit.

      Note: Exceptionally, non-systemic vaginal estrogen treatment is permitted.

    5. Calcitonin, or its derivatives, and calcimimetics (such as cinacalcet or etelcalcetide) at any dose within 12 months prior to Screening Visit.
    6. Calcitriol, alfacalcidol, or eldecalcitol within 3 months of the Screening Visit.
    7. Fluoride or strontium at any dose at any time prior to Screening Visit.
    8. Romosozumab or cathepsin K inhibitors received at any time prior to Screening Visit.
    9. Systemic (≥ 5 mg prednisone or equivalent per day for more than 10 days or cumulative ≥ 50 mg) within 3 months prior to Screening Visit.
    10. Other bone active drugs including anticonvulsants (except benzodiazepines, gabapentin, and pregabalin), heparin (including low molecular weight heparins), vitamin K (supplementation or therapeutic dose), vitamin K antagonists (e.g., warfarin, acenocumarol), emtricitabine, tenofovir, adefovir, systemic ketoconazole, adrenocorticotropic hormone, lithium, protease inhibitors, gonadotropin-releasing hormone agonist, aluminum, barbiturate, methotrexate, chemotherapeutic agents, cyclosporine, tacrolimus, or anabolic steroids at any dose within 3 months prior to Screening Visit. Prior/Concurrent Clinical Study Experience
  19. Participant is receiving or has received another product within 1 month or 5 half-lives of the other investigational product, whichever is longer, before study intervention administration in this study. Diagnostic Assessments
  20. Participant has DXA measurements where:

    1. Height, weight, or girth measurements may preclude accurate DXA measurements in the Investigator's opinion.
    2. BMD absolute value is consistent with a T-score \< -4.0 at the total hip or femoral neck.
  21. Participant has severe renal impairment (defined as participant in dialysis or with an \< 30 mL/min per MDRD formula).
  22. Participant has inadequate hepatic function ( and/or AST ≥ 2 × ).
  23. Participant presents with clinically significant leukopenia, neutropenia, or anemia as judged by the Investigator.

    Other Exclusion Criteria

  24. Participant has a known intolerance to calcium or vitamin D supplements.
  25. Participant has a history of prescription drug abuse or any illicit drug use within 6 months prior to Screening Visit.
  26. Participant has a history of alcohol abuse (defined as consuming more than 3 drinks on any day or more than 7 drinks per week) according to medical history within 6 months prior to Screening Visit.
  27. Participant is a smoker or has used nicotine and nicotine-containing products within 12 months of Screening Visit.
  28. Participant has a known sensitivity to mammalian cell-derived drug products.
  29. Participant is for any reason.
  30. Participant has any other conditions including clinically significant medical conditions/disorders/diseases, psychiatric status, or laboratory abnormalities that in the opinion of the Investigator might interfere with the participant's ability to participate in the study, would pose a risk to the participant's safety, or interfere with the study evaluation, procedure, or completion.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
392 participants (estimated)

Study arms

  • Experimental
    LY06006

    to be administered 2 doses to the patients at the main treatment period and 1 dose at the transition period.

    Biological: Denosumab

  • Active comparator
    EU Prolia

    to be administered 2 doses to the patients at the main treatment period and 1 dose at the transition period.

    Biological: Denosumab

Interventions

  • BiologicalDenosumab

    Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.

06

What researchers measure

Primary outcomes

  1. To demonstrate equivalent efficacy between LY06006 and EU-Prolia, in terms of BMD in female participants with postmenopausal osteoporosis;

    %CfB in lumbar spine BMD at Month 12

    Time frame: 12 months

  2. EU Marketing Authorization only: To demonstrate similar PD between LY06006 and EU-Prolia, in terms of the bone resorption marker sCTX in female participants with postmenopausal osteoporosis

    EU Marketing Authorization only: standardized AUEC0-6m (post first dose) of -%CfB in bone resorption marker sCTX over 6 months

    Time frame: 6 months

Secondary outcomes

  1. To provide additional comparative efficacy data of LY06006 with EU-Prolia in female participants with postmenopausal osteoporosis

    * %CfB in lumbar spine BMD at Month 6 * %CfB in total hip BMD at Months 6 and 12 * %CfB in femoral neck BMD at Months 6 and 12

    Time frame: 6-12 months

07

Study locations

39 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jul 2025, 27 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's planned 27 months is above that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
May 10, 2023
StartActual
Apr 5, 2023
Primary completionEst.
Jul 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Apr 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05853354
Responsible party
Sponsor
First posted
May 10, 2023
Start date
Apr 5, 2023
Primary completion
Jul 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Apr 26, 2024

Study contacts

Joe Tai
study chair · Luye Pharma Group Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion